Blog
Why Chronic Pain Isn't "All in One Place"
Chronic pain — which affects an estimated 20–30% of adults worldwide — is notoriously hard to treat, and a new review in The Neuroscientist (Rudd & Di Ieva, 2026) helps explain why: it isn't caused by one broken "pain spot" in the brain, but by five interacting brain networks (sensory, emotional/salience, rhythm-keeping, natural pain-relief, and body-signal prediction) falling out of sync with each other. Because different people's pain is driven by different combinations of these networks, the review argues that treatment should be matched to each patient's specific "pain phenotype" rather than applying a one-size-fits-all approach — sensory-dominant pain (like CRPS or post-stroke pain) may respond better to sensory-cortex targeting, while emotionally-driven pain may respond better to targeting the brain's emotional-salience regions. It's early-stage research, but it points toward a future of personalized, connectivity-guided pain treatment rather than a single universal fix.
Read More
Fibromyalgia Isn't "All in Your Head" — New Genetic Study Points to a Nervous System Disorder
For decades, people with fibromyalgia have heard some version of the same dismissal: that their pain is "all in their head," or that the condition isn't even real. A new study, published in Nature Medicine and co-led by researchers at the University of Toronto and Sinai Health, just delivered the strongest evidence yet that this dismissal was wrong. By analyzing genetic data from more than 2.5 million adults, including 55,000 people with fibromyalgia, scientists identified 26 regions of the genome linked to the condition, most of them tied to genes active in the brain and nervous system. That points to fibromyalgia being a neurological disorder rather than the autoimmune or psychological condition it's often mistaken for. One of the strongest genetic signals even turned up near HTT, the gene behind Huntington's disease, hinting at unexpected biological overlap between the two conditions. The researchers also found that fibromyalgia shares genetic roots with other conditions like irritable bowel syndrome, chronic low back pain, and PTSD, which may explain why these conditions so often show up together in the same people. Interestingly, even though fibromyalgia is diagnosed about three times more often in women, the genetic risk turned out to be the same across sexes, suggesting the gap comes down to hormones, environment, or how diagnoses get made rather than biology itself. The findings won't lead to a genetic test or a new treatment overnight, but they give researchers real, biological starting points after years of uncertainty, and the same team has now launched the Chronic Pain Genomics Consortium to dig into other chronic pain conditions next.
Read More
Ontario Now Covers a Promising Brain Therapy for Depression That Won't Go Away
Ontario is now offering free access to a brain stimulation therapy that could be life-changing for people with hard-to-treat depression. Starting this month, the province is publicly funding repetitive transcranial magnetic stimulation, or rTMS, for adults with treatment-resistant depression — meaning depression that hasn't improved after trying two or more antidepressant medications. About 1 in 5 Canadians with major depression falls into this category, and many end up in the emergency room struggling to find help. rTMS works by using magnetic pulses, applied through the scalp, to stimulate areas of the brain involved in mood regulation. Unlike electroconvulsive therapy (ECT), it doesn't require anesthesia or a seizure, and side effects are mild — mostly scalp discomfort or a temporary headache. Each session takes just three minutes, given five days a week for six weeks at an outpatient clinic, and about half of patients see meaningful improvement, with roughly a third going into remission that can last months or years. The Centre for Addiction and Mental Health (CAMH) is coordinating the rollout, which will support 18 devices across 15 sites province-wide, giving an estimated 2,250 Ontarians a year access to a treatment that was previously out of reach for many. It's a significant step toward closing the gap for people who've run out of options with standard medication.
Read More
A Tiny Implant Is Giving Long-Term Relief to People With the Toughest Depression
For people whose depression doesn't respond to medication or therapy — even after trying more than a dozen treatments — a small implanted device may finally offer lasting help. A major U.S. clinical trial found that vagus nerve stimulation (VNS), which uses a pacemaker-like device to send gentle electrical pulses to the vagus nerve, produced meaningful improvement in 69% of severely treatment-resistant patients after one year, and most of those gains held or even grew over the following year. Some patients who saw no benefit at first improved by year two, suggesting VNS can take time to work. The trial's participants had lived with depression for an average of 29 years, making this one of the sickest patient groups ever studied for the condition — and one in five ended up essentially symptom-free after two years. The results, while funded by the device's manufacturer, are now being used to push for Medicare coverage of a treatment that's been FDA-approved since 2005 but remains largely inaccessible to the patients who need it most.
Read More
A Gene Therapy Breakthrough for Knee Osteoarthritis?
Knee osteoarthritis doesn't always make headlines, but it quietly devastates lives: it's a leading cause of disability and chronic pain, drives opioid use, and costs the health system a lot in knee replacement surgeries. Current treatments — pain relievers, steroid shots, eventually a full knee replacement — only manage symptoms, since there's no cure. That may be changing. Genascence, a biotech led by CEO Thomas Chalberg, has developed a gene therapy called GNSC-001 that uses a single injection of a harmless virus to instruct knee joint cells to produce a protein that blocks the inflammation, pain, and cartilage damage driving the disease, offering the potential for longer-lasting relief than existing injections. After promising animal studies, the company's Phase 1b "Donatello" trial in 67 patients, backed by a $12 million award from the California Institute for Regenerative Medicine, showed the treatment was safe and led to real improvements in pain and function within six months, with one UC San Diego surgeon calling the results life-changing for some patients. The FDA has since granted the therapy a fast-track designation, and Genascence is preparing a larger pivotal trial for later this year or 2027, with hopes of eventually pricing it below the cost of a joint replacement.
Read More